- Home
- SNSE vs CMMB Comparison
SNSE vs CMMB Comparison
Compare SNSE & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNSE
- CMMB
- Stock Information
- Founded
- SNSE 2005
- CMMB 2004
- Country
- SNSE United States
- CMMB Israel
- Employees
- SNSE N/A
- CMMB N/A
- Industry
- SNSE Biotechnology: Pharmaceutical Preparations
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- SNSE Health Care
- CMMB Health Care
- Exchange
- SNSE Nasdaq
- CMMB Nasdaq
- Market Cap
- SNSE 14.5M
- CMMB 13.7M
- IPO Year
- SNSE 2021
- CMMB N/A
- Fundamental
- Price
- SNSE $11.71
- CMMB $3.32
- Analyst Decision
- SNSE Strong Buy
- CMMB Strong Buy
- Analyst Count
- SNSE 4
- CMMB 2
- Target Price
- SNSE $72.50
- CMMB $26.50
- AVG Volume (30 Days)
- SNSE 56.5K
- CMMB 266.9K
- Earning Date
- SNSE 11-13-2025
- CMMB 11-13-2025
- Dividend Yield
- SNSE N/A
- CMMB N/A
- EPS Growth
- SNSE N/A
- CMMB N/A
- EPS
- SNSE N/A
- CMMB N/A
- Revenue
- SNSE N/A
- CMMB N/A
- Revenue This Year
- SNSE N/A
- CMMB N/A
- Revenue Next Year
- SNSE N/A
- CMMB N/A
- P/E Ratio
- SNSE N/A
- CMMB N/A
- Revenue Growth
- SNSE N/A
- CMMB N/A
- 52 Week Low
- SNSE $5.00
- CMMB $2.39
- 52 Week High
- SNSE $18.35
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- SNSE 53.46
- CMMB 63.44
- Support Level
- SNSE $11.00
- CMMB $3.03
- Resistance Level
- SNSE $18.35
- CMMB $3.50
- Average True Range (ATR)
- SNSE 1.55
- CMMB 0.22
- MACD
- SNSE 0.36
- CMMB 0.02
- Stochastic Oscillator
- SNSE 27.83
- CMMB 75.79
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.